tbuckley/cabot-search huggingface dataset:
Next-generation finely controlled graded porous antibacterial bioceramics for high-efficiency vascularization in orbital reconstruction
Authors: Jingyi Wang, Yiyu Peng, Menglu Chen, Xizhe Dai, Lixia Lou, Changjun Wang, Zhaonan Bao, Xianyan Yang, Zhongru Gou, Juan Ye
Journal: Bioactive Materials (2022)

Eyeball loss due to severe ocular trauma, intraocular malignancy or infection often requires surgical treatment called orbital implant reconstruction to rehabilitate the orbital volume and restore the aesthetic appearance. However, it remains a challenge to minimize the postoperative exposure and infection complications due to the inert nature of conventional orbital implants. Herein, we developed a novel Ca–Zn-silicate bioceramic implant with multi-functions to achieve the expected outcomes. The porous hardystonite (Ca2ZnSi2O7) scaffolds with triply periodic minimal surfaces (TPMS)-based pore architecture and graded pore size distribution from center to periphery (from 500 to 800 μm or vice versa) were fabricated through the digital light processing (DLP) technique, and the scaffolds with homogeneous pores (500 or 800 μm) were fabricated as control. The graded porous scaffolds exhibited a controlled bio-dissolving behavior and intermediate mechanical strength in comparison with the homogeneous counterparts, although all of porous implants presented significant antibacterial potential against S. aureus and E. coli. Meanwhile, the pore size-increasing scaffolds indicated more substantial cell adhesion, cell viability and angiogenesis-related gene expression in vitro. Furthermore, the gradually increasing pore feature exhibited a stronger blood vessel infiltrating potential in the dorsal muscle embedding model, and the spherical implants with such pore structure could achieve complete vascularization within 4 weeks in the eyeball enucleation rabbit models. Overall, our results suggested that the novel antibacterial hardystonite bioceramic with graded pore design has excellent potential as a next-generation orbital implant, and the pore topological features offer an opportunity for the improvement of biological performances in orbital reconstruction.
Differentiation between ischemic and non-ischemic dilated cardiomyopathy based on left atrioventricular plane displacement during dobutamine echocardiography Konstadina P. Bouki, Theodoros Kakavas, Konstadinos Kostopoulos, Georgios Tsamis, Loukianos Rallidis, Kyriakos Poulopoulos, Takis Xydas, Thomas Apostolou, Evaggelos Papasteriadis. Nikaia General Hospital, Pireaus, Greece
Journal: Journal of the American College of Cardiology (2001)
Distinct differences in genomic profile of gastric and gastroesophageal junction adenocarcinoma.
Authors: Masaya Nakauchi, Henry S. Walch, Walid Khaled Chatila, Thinh Tran, Elvira Lise Vos, Smita Sihag, Laura H. Tang, Daniel G. Coit, Zsofia Kinga Stadler, Yelena Y. Janjigian, Steven Brad Maron, Geoffrey Yuyat Ku, David H. Ilson, David B. Solit, Nikolaus Schultz, Daniela Molena, Vivian E. Strong
Journal: Journal of Clinical Oncology (2022)

345 Background: Gastroesophageal junction cancer (GEJC) and gastric cancer (GC) are frequently studied together as one disease. Genomic profiles between the two disease sites have not been well characterized. We aimed to characterize molecular differences between the two disease sites. Methods: We collected data between January 2010 and December 2019 from a prospectively maintained database of GEJC and GC at our center. GEJC was defined according to the Siewert type 1 to 3 classification. Patients who underwent surgical resection and had MSK-IMPACT (MSK-Integrated Mutation Profiling of Actionable Cancer Targets) sequencing performed on their primary tumor were included in this analysis. Results: Two hundred and seventy-four samples were analyzed; 156 (56.9%) GEJC and 118 (43.1%) GC patients. Regarding molecular subtypes, the GEJC group had a higher frequency of chromosomally instable tumors compared to the GC cohort (55.1% vs. 25.4%, p &lt; 0.001). The fraction of genome altered (FGA) was significantly higher in the GEJC group (p &lt; 0.001). TP53 (75.3% vs. 31.9%, p &lt; 0.001, q &lt; 0.001), CDKN2A (17.1% vs. 4.3%, p = 0.002, q = 0.02), and MDM2 (6.8% vs. 0%, p = 0.007, q = 0.033) were more frequently altered in the GEJC group, whereas CDH1 (2.7% vs. 9.6%, p = 0.037, q = 0.118) and RHOA (0% vs. 6.4%, p = 0.003, q = 0.02) were more frequently altered in the GC group. The GEJC group also had a higher frequency of alterations in the cell cycle pathway compared to the GC patients (36.3% vs. 11.7%, p &lt; 0.001, q &lt; 0.001). Conclusions: There are distinct differences in genomic profiles between GEJC and GC with a higher frequency of mutations in TP53, CDKN2A, MDM2, and cell cycle pathway in the GEJC patients, that may have potential implications in evaluating optimal treatment strategies with targeted therapy.
Medical practice and the new curricula
Authors: E. D. Pellegrino
Journal: JAMA (1970)

Professions, like all closed systems, tend to self-replication. They change only when social forces threaten to take the initiative from them, and when, as is now the case, they are painfully reminded that professions themselves are ultimately instruments of specific social purpose. To speak, therefore, of the impact of curricular reform on practice is to belie a certain presumption common to educators and practitioners alike. New curricula arise primarily in response to unfilled social, political, and scientific needs. A new curriculum at first reshapes practice along more socially relevant lines. It then perpetuates the prevalent care system until new external pressures generate another wave of educational reforms. It is with this cycle in mind that I shall examine some of the probable effects of the current curricular revolution on our medical care system. It was Flexner's rather shocking revelations of the insensitivity of medical education to the relevance of the
Nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Preliminary results from an open-label, single-arm, phase 2 study.
Authors: Zhichao Jiang, Wen Zhang, Lin Yang, Yongkun Sun, Yun-Bo Zhao, Wei Deng, Ai-Ping Zhou
Journal: Journal of Clinical Oncology (2022)

293 Background: Anti-PD-1 antibody showed some efficacy but was not superior to mono-chemotherapy in the second line (2L)-treatment of advanced or metastatic G/GEJA. The combination of chemotherapy and anti-PD-1 antibody has been demonstrated to have a synergistic effect. Nab-paclitaxel (nab-PTX) was one of the most common used 2L-regimens in Asia. Therefore, we aimed to assess efficacy and safety of nab-PTX plus sintilimab in patients (pts) with advanced G/GEJA in this study. Methods: This was an open-label, single-arm, phase 2 study undertaken at the National Cancer Center of China. Eligible patients were aged 18 to 75 years old with histological or cytological diagnosis of G/GEJA, had an ECOG PS of 0 or 1 and measurable disease according to the RECIST v 1.1 after 1L-chemotherapy with fluoropyrimidine and platinum. Patients received nab-PTX (125mg/m 2, d1 &amp; d8, ≤ 6 cycles) and sintilimab (200mg, d1, ≤ 2 years) every 3 weeks. The primary endpoint was objective response rate (ORR). The threshold 2L-therapy ORR was set to 13% and the expected ORR was 30%. Results: From Nov 4, 2019, to Sep 15, 2021, 36 pts were enrolled and 31 pts were eligible for response assessment. Median age was 58y and 58.1% were men. Median follow-up time was 7.8 months (95% CI 3.299-12.301). ORR was 41.9%. One patient (pt) achieved complete response and 12 pts acquired partial response. Disease control rate was 83.9%. Median progression free survival was 5.2 months (95%CI 3.556-6.848). The most common treatment-related adverse events (TRAEs) of grade 3-4 were neutropenia (19.4%), leukopenia (9.7%), aspartate aminotransferase increased (9.7%), thrombocytopenia (3.2%) and fatigue (3.2%). No treatment-related deaths occurred. The potential immune-related adverse events (irAEs) were hypothyroidism (3 pts [9.7%]), pneumonia (1 pt [3.2%]), myocardial enzyme elevation without any syndrome (1 pt [3.2%]) and isolated ACTH deficiency (1 pt [3.2%]). Most of the potential irAEs were grade 1 or 2. Only one patient developed grade 3 colitis. Furthermore, 3 pts (9.7%) with diabetes developed hyperglycemia of grade 3 and 1 pt (3.2%) endured acute myocardial infarction who had a history of coronary heart disease. Conclusions: Second-line nab-PTX plus sintilimab showed promising anti-tumour activity with a manageable safety profile in pts with advanced or metastatic G/GEJA preliminarily. These results warrant further accrual and evaluation. This study is still recruiting. Clinical trial information: NCT04140318. Research Sponsor: Innovent Biologics and CSPC Ouyi Pharmaceutical Co. Ltd. Clinical trial information: NCT04140318.
Maintenance therapy following an anti-EGFR-based induction regimen in metastatic colorectal cancer (mCRC): A network meta-analysis of clinical trials.
Authors: Laércio Lopes da Silva, Pedro Nazareth Aguiar, Renata D'Alpino, Rodrigo Dienstmann
Journal: Journal of Clinical Oncology (2022)

128 Background: A fluoropyrimidine with or without bevacizumab is often used in clinical practice as maintenance therapy after a first-line chemotherapy + bevacizumab induction in mCRC. However, the role of maintenance following an anti-EGFR-based induction and the optimal regimen are not well established. Methods: We searched PubMed and conferences’ proceedings for clinical trials assessing maintenance therapy after first-line treatment for RAS WT mCRC. Two independent reviewers excluded single-arm studies and retrospective reports from trials that were not designed to assess maintenance therapy. We used the method of Guyot et. al. to obtain the individual patient data, followed by a Cox procedure to derive the survival hazard ratios (HR) from studies that did not report that value. Safety analysis included grade 3-4 asthenia, neuropathy, neutropenia, rash, and diarrhea. We performed a random-effects bayesian network metanalysis using the package “GeMTC R Package” to compare all treatment strategies included (anti-EGFR, anti-EGFR + chemotherapy [CT], CT alone, and observation). The risk of bias was assessed according to the Cochrane Handbook for Systematic Reviews of Interventions. Results: The systematic review retrieved 145 studies from which 142 were excluded. Two additional studies were found in the Conferences’ Proceedings review. Consequently, 5 studies were included in this NMA. In terms of Progression-Free Survival (PFS), there was a benefit of anti-EGFR and anti-EGFR+CT versus CT alone (HR 0.63 [95%CrI 0.31-1.30] and 0.72 [95%CrI 0.41-1.30], respectively). The rank probability of anti-EGFR being the best option considering PFS was 61%. In terms of Overall Survival (OS), the benefit of anti-EGFR and anti-EGFR+CT versus CT alone was statistically weak (HR 0.92 [95%CrI 0.54-1.50] and 0.84 [95%CrI 0.57-1.20], respectively). The rank probability of anti-EGFR+CT be the best option in terms of OS was 51%. Comparing anti-EGFR versus anti-EGFR+CT resulted in no statistically significant difference. Anti-EGFR-containing regimens increased the rate of rash and diarrhea compared to CT alone (RR 11.23 and 1.23, respectively). The risk of bias was average low, except for the unclear risk of selection bias linked to unpublished studies. Conclusions: Anti-EGFR±CT maintenance therapy improves PFS and OS compared to CT alone or observation in RAS WT mCRC, with manageable safety profile.
Significance of monocyte chemoattractant protein-1 in human atherosclerosis: Assessment in chronic hemodialysis Kengo F. Kusano, Yoichi Nakamura, Kazufumi Nakamura, Hitoshi Kusano, Isao Kusano, Tohru Ohe. Cardiovascular Medicine, Okayama University Medical School, Okayama, Japan, Fukushima Naika Clinic, Okayama, Japan
Journal: Journal of the American College of Cardiology (2001)
Nostrum Prescribing.
Authors: John Inglis
Journal: JAMA (1907)

Pueblo, Colo., Nov. 28, 1907. <h3>To the Editor:</h3> —I spent last month in New York City with some old-time friends in whose home is a small boy. A few days before my arrival this boy was out of sorts, and the father went to their physician for a prescription. Imagine my surprise to discover that the prescription that father received was for a bottle of Castoria—and there it was, literature, wrappers and all. I looked up the directory of the American Medical Association only to find that this physician is not only a member of the state society, but also of the American Medical Association. And he orders Castoria! Is it because the children cry for it? Riding up Fifth Avenue the other day the elegant home of Castoria's promoter was pointed out, and not far from that the home of<i>Medical Brief</i>Lawrence of "ethical proprietary" medicine fame. When
Lim HW, Gilchrest BA, Cooper KD, Bischoff-Ferrari HA, Rigel DS, Cyr WH, Miller S, DeLeo VA, Lee TK, Demko CA, Weinstock MA, Young A, Edwards LS, Johnson TM, Stone SP. Sunlight, tanning booths, and vitamin D. J Am Acad Dermatol 2005;52:868-76 (May)
Journal: Journal of the American Academy of Dermatology (2005)
TCTAP A-090 Impact of Vessel Size on Stent Patency Following Self-expanding Stents Implantation in Superficial Femoral Artery Lesions
Authors: Kojiro Miki, Koji Yanaka, Nagataka Yoshihara, Kenji Kawai, Takahiro Imanaka, Hirokuni Akahori, Tohru Masuyama, Masaharu Ishihara
Journal: Journal of the American College of Cardiology (2018)
Editorial Board
Authors: Donald Leung, Stanley Szefler, Colo Associate, Andrea Apter, Pedro Philadelphia, Bruce Avila, Baltimore Bochner, Joshua Boyce, Robert Bush, Fred Finkelman, Dennis Ledford, Tampa Fla, Deborah Meyers, Luigi Notarangelo, David Peden, Harald Renz, Marburg Germany, Marc Rothenberg, William Shearer, Scott Sicherer, New York, Erika Von Mutius, Statistics Editor, Vernon Chinchilli
Journal: Journal of Allergy and Clinical Immunology (2012)
Kidney Stones
Authors: Tracy Hampton
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
COVID-19 Vaccines Have Been Available in the US for More Than a Year—What’s Been Learned and What’s Next?
Authors: Rita Rubin
Journal: JAMA (2022)

ore than a year has passed since people began receiving the first authorized COVID-19 vaccine in the US.By early January of this year, nearly 210 million people, or two-thirds of the eligible population, had received either 2 doses of an mRNA vaccine or 1 dose of an adenovirus vaccine to protect against SARS-CoV-2 infection.On top of that, 75 million people, or more than a third of those eligible, had received a booster dose.While millions of COVID-19 cases and hospitalizations have been prevented and hundreds of thousands of lives saved, the pandemic still rages, with US daily case and hospitalization counts hitting record highs beginning right around the anniversary of the first vaccinations outside clinical trials.
JAMA Reference Directories
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PHARMACEUTICAL EXHIBIT.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).
Authors: Arvind Dasari, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim Halil Halil Sahin, Dustin A. Deming, Philip Agop Philip, Theodore S. Hong, Norman Wolmark, Greg Yothers, Thomas J. George, Christopher Hanyoung Lieu
Journal: Journal of Clinical Oncology (2022)

TPS212 Background: Currently, there are no biomarkers validated prospectively in randomized studies for resected colon cancer (CC) to determine need for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) shed into the bloodstream represents a highly specific and sensitive approach (especially with serial monitoring) for identifying microscopic or residual tumor cells in CC patients (pts) and may outperform traditional clinical and pathological features in prognosticating risk for recurrence. CC pts who do not have detectable ctDNA (ctDNA-) are at a much lower risk of recurrence and may not need AC. Furthermore, for CC pts with detectable ctDNA (ctDNA+) who are at a very high risk of recurrence, the optimal AC regimen has not been established. We hypothesize that for pts whose colon cancer has been resected, ctDNA status may be used to risk stratify for making decisions about AC. Methods: In this prospective phase II/III trial, up to 1,912 pts with resected stage III A, B (all pts) and stage II, IIIC (ctDNA+ only) CC will be enrolled. Based on the post-operative ctDNA status using Natera’s Signatera assay, those who are ctDNA- (Cohort A) will be randomized to immediate AC with fluoropyrimidine (FP) + oxaliplatin (Ox) for 3-6 mos per established guidelines vs serial ctDNA monitoring. Patients who are ctDNA+ post-operatively or with serial monitoring (Cohort B) will be randomized to FP + Ox vs more intensive AC with addition of irinotecan (I) for 6 mos. The primary objectives for Cohort A are time to ctDNA+ status (phase II) and disease-free survival (DFS) in phase III in the immediate vs delayed AC arms. The primary objective for Cohort B is DFS in the FP + Ox vs FP + Ox + I arms for both phase II and phase III portions of the trial. Secondary objectives include prevalence of detectable ctDNA post-operatively, time-to event outcomes (overall survival &amp; time to recurrence) by ctDNA status, and the assessment of compliance to adjuvant therapy. Biospecimens including archival tumor tissue, post-operative and serial matched/ normal blood samples will be collected for exploratory correlative research. Study will activate in early 2022 across the NCTN. NCT#: Pending. Support: U10-CA-180868, -180822; UG1CA-189867; Natera.
Update: Severe Acute Respiratory Syndrome—Toronto, Canada, 2003
Journal: JAMA (2003)

Severe acute respiratory syndrome (SARS) was first recognized in Toronto in a woman who returned from Hong Kong on February 23, 2003 (1). Transmission to other persons resulted subsequently in an outbreak among 257 persons in several Greater Toronto Area (GTA) hospitals. After implementation of provincewide public health measures that included strict infection-control practices, the number of recognized cases of SARS declined substantially, and no cases were detected after April 20. On April 30, the World Health Organization (WHO) lifted a travel advisory issued on April 22 that had recommended limiting travel to Toronto. This report describes a second wave of SARS cases among patients, visitors, and health-care workers (HCWs) that occurred at a Toronto hospital approximately 4 weeks after SARS transmission was thought to have been interrupted. The findings indicate that exposure to hospitalized patients with unrecognized SARS after a provincewide relaxation of strict SARS control measures probably contributed to transmission among HCWs. The investigation underscores the need for monitoring fever and respiratory symptoms in hospitalized patients and visitors, particularly after a decline in the number of reported SARS cases.
Fe(III)‐Shikonin Supramolecular Nanomedicine for Combined Therapy of Tumor via Ferroptosis and Necroptosis (Adv. Healthcare Mater. 2/2022)
Authors: Wenjie Feng, Wanrui Shi, Shuwei Liu, Huiwen Liu, Yi Liu, Pengfei Ge, Hao Zhang
Journal: Advanced Healthcare Materials (2022)

Enzyme-Responsive Drug Release In article number 2101926, Yi Liu, Pengfei Ge, Hao Zhang, and co-workers construct a Fe(III)-Shikonin metal-polyphenol-coordinated supramolecular nanomedicine for combined therapy of tumors. The as-prepared nanomedicine will disassemble into Fe2+ and Shikonin in response to the high concentration of glutathione in tumor cells, followed by the up-regulation of the intracellular reactive oxygen species level and the depletion of the intracellular glutathione level, resulting in the tumor cell death via ferroptosis and necroptosis.